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Abstract
Purpose To compare the accuracy of PET/MR imaging with
that of FDG PET/CT and to determine the MR sequences
necessary for the detection of liver metastasis using a
trimodality PET/CT/MR set-up.
Methods Included in this single-centre IRB-approved study
were 55 patients (22 women, age 61±11 years) with suspected
liver metastases from gastrointestinal cancer. Imaging using a
trimodality PET/CT/MR set-up (time-of-flight PET/CT and
3-T whole-body MR imager) comprised PET, low-dose CT,
contrast-enhanced (CE) CT of the abdomen, and MR with
T1-W/T2-W, diffusion-weighted (DWI), and dynamic CE
imaging. Two readers evaluated the following image sets for
liver metastasis: PET/CT (set A), PET/CECT (B), PET/MR
including T1-W/T2-W (C), T1-W/T2-W with either DWI (D)
or CE imaging (E), and a combination (F). The accuracy of
each image set was determined by receiver-operating charac-
teristic analysis using image set B as the standard of reference.
Results Of 120 liver lesions in 21/55 patients (38 %), 79
(66 %) were considered malignant, and 63/79 (80 %) showed
abnormal FDG uptake. Accuracies were 0.937 (95 % CI
89.5 – 97.9 %) for image set A, 1.00 (95 % CI
99.9 – 100.0 %) for set C, 0.998 (95 % CI 99.4 – 100.0 %)
for set D, 0.997 (95 % CI 99.3 – 100.0 %) for set E, and 0.995
(95 % CI 99.0 – 100.0 %) for set F. Differences were signif-
icant for image sets D – F (P <0.05) when including lesions
without abnormal FDG uptake. As shown by follow-up im-
aging after 50 – 177 days, the use of image sets D and both
sets E and F led to the detection of metastases in one and three
patients, respectively, and further metastases in the contralat-
eral lobe in two patients negative on PET/CECT (P= 0.06).
Conclusion PET/MR imaging with T1-W/T2-W sequences
results in similar diagnostic accuracy for the detection of liver
metastases to PET/CECT. To significantly improve the char-
acterization of liver lesions, we recommend the use of dynam-
ic CE imaging sequences. PET/MR imaging has a diagnostic
impact on clinical decision making.
Keywords Liver metastasis . Hepatology . Oncology .
PET/MRI . PET/CT .Multimodality imaging
Introduction
Metastatic disease limited to or predominantly in the liver is
increasingly treated with a local therapeutic approach includ-
ing resection, ablation, or embolization [1–3]. These recent
advances in treatment, especially the implementation of atyp-
ical parenchyma-sparing resections together with neoadjuvant
chemotherapy, have reduced mortality and thereby increased
the number of patients who are candidates for hepatic surgery.
The 5-year overall survival rate after resection of hepatic
colorectal liver metastases has increased to 35 % [4]. This
improved outcome is not only attributable to improved
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therapeutic management [5] but also to accurate diagnosis for
patients selection by means of PET and CT [6, 7]. PET/CT
facilitates the selection of appropriate patients with a tumour
load restricted to the liver or who have only limited extrahe-
patic disease [8]. This directly translates into better survival
after liver resection since extrahepatic tumour is detected in an
additional one of four patients [8]. Besides detection of extra-
hepatic disease, exact localization and detection of all hepatic
disease is crucial for local therapeutic approaches. With re-
spect to the detection of liver metastases, PET/CT regularly
comprises abdominal contrast-enhanced (CE) CT, which is
the primary imaging modality with reported sensitivities rang-
ing up to 85 % [9]. Despite such high sensitivities, MR
imaging outperforms CECT in the hepatic assessment of
metastatic disease, especially in patients with small lesions
because of increased contrast resolution and multiparametric
imaging [10, 11].
For these reasons, an integrated approach using PET/MR
imaging might result in improvements over PET/CT in the
detection of metastases [12, 13]. However, the MR imaging
techniques needed in the clinical setting to significantly im-
prove the detection and characterization of liver metastases in
PET/MR imaging remain uncertain.
In this study, we compared the diagnostic accuracy of PET/
MR imaging with that of PET/CT and determined MR se-
quences necessary for the detection of liver metastases using
a trimodality PET/CT/MR set-up.
Materials and methods
Patients
This study followed the principles of the Declaration of Hel-
sinki and was approved by the institutional review board and
the ethics review board. All patients gave written informed
consent.
This was a prospective, single-centre, observational, cross-
sectional study. Between March 2012 and March 2013, 55
consecutive patients were enrolled (33 men and 22 women;
mean age 61±11 years, range, 32 – 79 years), all of whom
presented with malignancies that primarily metastasize to the
liver (colorectal carcinoma in 41 patients, pancreatic carcino-
ma in 5, gastrointestinal stromal tumour in 4, cholangiocellular
carcinoma in 3, and gastroesophageal carcinoma in 2). The
inclusion criterion was referral for FDG PET/CT as part of a
clinically indicated oncological baseline staging or restaging at
our institution (55 patients). General exclusion criteria for
CECT were pregnancy, renal insufficiency and hypersensitiv-
ity to iodine-containing contrast material. Exclusion criteria for
MR imaging were pacemakers, metallic implants, and severe
claustrophobia as well as renal insufficiency. None of the
patients was excluded on the basis of these criteria.
PET/CT imaging
All patients fasted for at least 4 h before injection of a standard
dose of 300 MBq. The glucose level was measured before
scanning. None of the patients showed elevated glucose levels
(<8 mmol/L). After a standardized uptake time of 60 min,
patients were placed on a dedicated CT- and MR-compatible
examination table in the supine position. PET/CT and MR
imaging was performed on a trimodality PET/CT/MR set-up
(full ring, time-of-flight Discovery PET/CT 690, 3 T Discov-
ery MR 750; both GE Healthcare, Waukesha, MI). PET and
unenhanced low-dose CT data were acquired from the mid-
thigh to the vertex of the skull. PET data were acquired in 3-D
time-of-flight mode with a scan duration of 2 min per bed
position, an overlap of bed positions of 23% and an axial field
of view of 153 mm. The emission data were corrected for
attenuation using the low-dose CT data and iteratively recon-
structed (matrix size 256×256, Fourier rebinning) using VUE
Point FX (GE Healthcare) with three iterations (18 subsets).
CECT and non-enhanced CT data for diagnostic interpre-
tation and for attenuation correction were acquired using a
64-slice CT scanner. First, a low-dose CT scan was performed
using the following parameters: 40 mAs, 140 kVp, 0.5 s/tube
rotation, pitch 1.7, slice thickness 3.75 mm. This CT scan was
performed during breath-holding in the non-forced expiratory
position. Subsequently, abdominal CECTwas also performed
during breath-holding in the non-forced expiratory position
after intravenous injection of 100 mL iopromide contrast
material (Visipaque 320, iodine 320 mg/mL; Amersham
Health, Munich, Germany). Imaging parameters were as fol-
lows: 100 – 200 mAs attenuation-based tube current modula-
tion (auto mAs), 120 kVp, 0.5 s/tube rotation, pitch 1.7, slice
thickness 2.00 mm. The total average imaging time for
PET/CT was 14±4 min.
All CT images of the abdomen were reconstructed using
adaptive iterative reconstruction with a soft-tissue convolution
kernel at a standardized window setting (window width
350 HU, window level 50 HU). CT images were additionally
displayed with a dedicated liver window setting (window
width 150 HU, window level 100 HU) to improve soft-
tissue contrast between normal liver tissue and liver lesions.
PET/MR imaging
MR imaging data were acquired using a dedicated radiofre-
quency coil (32 Channel torso coil; GE Healthcare). The
imaging protocol included transverse T2-weighted (T2-W)
fast spin-echo sequence with periodically rotated overlapping
parallel lines with enhanced reconstruction (PROPELLER;
GE Healthcare). For diffusion-weighted imaging (DWI), a
spin-echo single-shot echo-planar imaging sequence was used
with diffusion-sensitizing gradients applied along the x , y, and
z axes (i.e. isotopic) before and after 180° pulses; these images
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were used to synthesize isotopic transverse images (b values
0, 400, and 800 s/mm2). T1-W data were acquired with a 3-D
dual-echo fast spoiled gradient-recalled-echo pulse sequence
(liver accelerated volume acquisition, LAVA-Flex; GE
Healthcare) before and after administration of contrast mate-
rial. Imaging was performed during the hepatic arterial, portal
venous and extracellular phases after the intravenous injection
of gadodiamide (Omniscan; Amersham Health, Munich, Ger-
many) at a dose of 0.1 mmol/kg bodyweight and a flow rate of
2 mL/s, followed by a 20-mL saline bolus. An online two-
point Dixon-based technique with a dedicated phase correc-
tion algorithm was used to decompose and extract water-only
(i.e. fat-suppressed) images from the dual-echo acquisition.
MR acquisition parameters are provided in Table 1.
Image analysis
Imageswere analysed and postprocessed on a dedicated work-
station (Advantage Windows, version 4.6; GE Healthcare).
Two experienced readers (two physicians, one holding
board certifications in both nuclear medicine and radiology,
and the other a board-certified radiologist, with 10 and 7 years
experience in abdominal imaging, respectively) evaluated all
image sets in consensus and random order. Six image sets
were analysed for each patient (Table 2):
Set A: PET and unenhanced low-dose CT images
Set B: PET, unenhanced low-dose CT and CECT images
Set C: PET with T1-W and T2-W images
Set D: PETwith T1-W, T2-W and DWI images
Set E: PET with T1-W, T2-W and CE T1-W images
Set F: PETwith T1-W, T2-W, DWI and CE T1-W images
During the evaluation of image sets C – F, the readers had
available the PET part of the PET/CT dataset, the nonfused
MR images as well as any possible fused PET/MR images. To
minimize any recall bias, the reading sessions were separated
by at least 2 weeks. Neither reader was aware of the results of
other imaging studies or clinical information including sur-
gery findings or histopathological examinations. All images
of each image set were evaluated in random order. Malignant
liver lesions were diagnosed on PET when abnormal focal
FDG uptake was observed on PET images not attributable to
physiological accumulations. On CT, any hypodense liver
lesion with ill-defined margins, appearing hypoperfused
or with irregular peripheral enhancement was defined as
metastasis [14].
On MR imaging, a liver metastasis was defined as a lesion
with ill-defined borders, irregular shape or signal intensity not
consistent with fluid on non-enhanced T1-W and T2-W im-
ages and features not consistent with haemangioma, adenoma
or focal nodular hyperplasia [15]. Regarding DWI, any dis-
tinct focus with increased signal intensity compared to the
signal intensity of the surrounding normal liver parenchyma
was considered a malignant lesion if the ADC values of the
lesion were equal to or lower than the ADC values of the
healthy surrounding tissue and signal characteristics on T1-W
and T2-W images were not consistent with a benign lesion
[15, 16]. On CE MR images liver lesions were defined as
metastases if enhancement criteria previously described and
not typical of haemangioma, adenoma or focal nodular hyper-
plasia were present [17]. Liver lesions were graded on a five-
point confidence scale ranging fromdefinitely benign (grade 1)
through indeterminate lesions (grade 3) to definitely malignant
(grade 5) according to the features mentioned above.
The nuclear medicine physician and the radiologist were
told to rely upon criteria from daily practice and decide
whether a lesion visible on PET, CT or MRI images, or all
images, was benign or malignant. Segmental liver anatomy
was used for location [18]. The maximum diameter of the
lesion was measured with an electronic calliper tool provided
by the software.
Potential diagnostic impact
Results of PET/CECT were considered the standard of refer-
ence for the assessment of malignant liver lesions on a per-
lesion and per-patient basis. In patients with liver lesions on
image set A and sets C – F that were not detected by the
standard of reference (i.e. false-positive), additional character-
ization of malignant liver lesions was based on follow-up
imaging after 50 – 177 days (median 139 days) by repeated
PET/CECT or MR imaging. Liver lesions that were detected
by the standard of reference but missed on image set A and
sets C – F were classified as false-negative. A radiologist who
was not involved in the data reading retrospectively
reclassified such liver lesions according to the aforementioned
imaging features and taking change in FDG uptake, change in
Table 1 Acquisition parameters for diagnostic MR sequences
Parameter T2-W
FSE
DW
SS-EPI
T1-W 3-D
FSPGRa
Repetition time/echo time (ms) 16,000/90 13,000/63 4.3/2.3
Flip angle (°) 140 90 14
Inversion time (ms) NA 110 NA
Section thickness/increment (mm) 6.0/7.0 6.0/7.0 5.0/2.5
Parallel imaging acceleration factor 2 2 2
Receiver bandwidth (kHz) 125 250 166
Contrast material administration No No Yes
Acquisition time <6 min 2 min 15 s
T2-W FSE T2-weighted fast spin-echo sequence, DW SS-EPI diffusion-
weighted single-shot echo planar imaging, T1-W 3-D FSPGR T1-weight-
ed three-dimensional fast spoiled gradient-recalled-echo pulse sequence;
NA not applicable
a Acquired before and after contrast material administration
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lesion size, or appearance of new lesions into account if
present [19].
A potential diagnostic impact was defined as any newly
discovered malignant liver lesion in a segment that was neg-
ative for malignant liver lesions on images of set B.
Statistical analysis
Sample size was determined on a per-lesion basis. By includ-
ing more than 78 (i.e. 79) malignant liver lesions, a McNemar
test with a type I error of 0.05 had >80 % power (81 %) to
detect an increase in sensitivity and specificity of 17 % and
3 %, respectively [12]. Quantitative data are expressed as
means±standard deviation if normally distributed (as tested
using the Shapiro-Wilk test), or as medians with ranges if
nonnormally distributed. Categorical data are given as abso-
lute numbers and percentages.
The mean diameter of malignant liver lesions (i.e. only
those lesions that were graded 4 or 5) with abnormal FDG
uptake were compared with the mean diameter of those with-
out abnormal FDG uptake using an independent samples
t test. The sensitivity, specificity, positive predictive value
and negative predictive value were calculated from chi-
squared tests of contingency. The 95 % confidence intervals
were calculated from binomial expressions. Diagnostic per-
formance is presented and compared on a per-lesion and a per-
patient basis (i.e. at least one malignant liver lesion in the
patient) using the nonparametric McNemar test for related
variables. A per-lesion analysis was carried out using seg-
ments depicted without malignant liver lesions as negative.
Image set B served as the standard of reference. Binary values
of 0 (benign) and 1 (malignant) were assigned to lesions with a
rating of 3 or less and to lesions with a rating of 4 or more,
respectively.
A receiver operating characteristic curve was fitted to each
reader’s confidence rating for liver lesion characterization.
The accuracy was estimated by calculating the area under
the receiver operating characteristic curve (AUC).
A P value <0.05 was considered to indicate statistical
significance. All statistical analyses were performed using
IBM SPSS statistics software (release 21.0; Chicago, IL).
Results
Patients
The primary malignancy was proven in all patients by means
of histopathology. The presence of metastatic liver disease
was proven by histopathology in 37 patients (67 %) and/or
on follow-up imaging in 48 patients (87 %). Of the 55 pa-
tients, 39 (71 %) had never had chemotherapy or radiotherapy
prior to imaging. The remaining 16 patients (29 %) had
chemotherapy between 34 and 709 days before imaging (me-
dian 356 days). Of these 16 patients, 8 (50 %) had also
previously undergone hepatic surgery for metastasis resection,
right hemihepatectomy in 4 (50%), left hemihepatectomy in 2
(25 %), and segment oriented resection in 2 (25 %, two
segments each).
PET/CT
PET/CECT detected a total of 120 liver lesions in 21 of the 55
patients (38 %). All lesions were located in 35 out of 411
present segments (8.5 %), whereas no lesions were detected in
376 segments (91.5 %). Regarding the maximum diam-
eter of lesions, 48 lesions were smaller than or equal to
10 mm (mean 7.4 mm, range 3 – 10 mm), 72 lesions were
larger than 10 mm (mean 30.4 mm, range 11 – 100 mm). Of
these 120 lesions, 79 were rated as malignant (66 %) whereas
41 lesions (34 %) were considered benign by the standard of
reference.
Of the 79 malignant lesions, 63 demonstrated abnormal
FDG uptake (80 %). The size distribution of lesions according
to abnormal FDG uptake is shown in Fig. 1. The mean
diameter of malignant lesions with abnormal FDG uptake
was significantly (P <0.05) larger than that of lesions without
abnormal FDG uptake.
PET/MR imaging
The diagnostic accuracies of the evaluations with the different
image sets are shown in Table 3.When plotting the confidence
level with regard to the presence or absence of malignant
Table 2 Contents of the image
sets of the six reading sessions
T2-W FSE T2-weighted fast
spin-echo sequence, T1-W 3-D
DE GRE T1-weighted three-di-
mensional dual-echo gradient-
recalled-echo pulse sequence,
DW SS-EPI diffusion-weighted
single-shot echo planar imaging
Image
set
PET Non-enhanced
low-dose CT
Contrast-
enhanced
abdominal CT
T2-W
FSE
Non-enhanced
T1-W
3-D DE GRE
DW
SS-EPI
Contrast-enhanced
T1-W 3-D
DE GRE
A ● ●
B ● ●
C ● ● ●
D ● ● ● ●
E ● ● ● ●
F ● ● ● ● ●
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lesions as shown by the standard of reference, the ROC
analyses revealed an AUC of 0.937 (95 % CI 89.5 – 97.9 %,
P <0.001) for image set A, 1.00 (95 % CI 99.9 – 100.0 %,
P <0.001) for set C, 0.998 (95 % CI 99.4 – 100.0 %,
P <0.001) for set D, 0.997 (95 % CI 99.3 – 100.0 %,
P <0.001) for set E, and an AUC of 0.995 (95 % CI
99.0 – 100.0 %, P <0.001) for set F (Fig. 2a). Differences in
AUC for liver lesion characterization were more pronounced
when only lesions without abnormal FDG uptake were in-
cluded (Fig. 2b). In lesions without abnormal FDG uptake,
ROC analyses revealed an AUC of 0.686 (95 % CI
51.0 – 86.1 %, P <0.001) for image set A, 0.994 (95 % CI
97.9 – 100.0 %, P <0.001) for set C, 0.973 (95 % CI
92.9 – 100.0 %, P <00.001) for set D, 0.955 (95 % CI
90.6 – 100.0 %, P <0.001) for set E, and an AUC of 0.946
(95 % CI 88.4 – 100.0 %, P <0.001) for set F. As compared to
the standard of reference, differences in accuracy were signif-
icant for image set A (P <0.001), set D (P <0.05), set E
(P <0.01), and set F (P <0.01) when including lesions without
abnormal FDG uptake only.
Potential diagnostic impact
Image set A produced 20 false-negative and 4 false-positive
ratings (P <0.01). Image sets C to F were not associated with
false-negative ratings (Fig. 3), but produced false-positive
ratings in 8 of 55 patients (15 %) compared with the standard
of reference: set C produced 1 false-positive rating (P =1.00),
set D produced 6 (P <0.05), set E produced 11 (P <0.01), and
set F produced 12 (P <0.001).Additional malignant liver le-
sions were detected on follow-up imaging in one patient using
image set D and in the same three patients using both image
sets E and F, which were negative using image set B including
PET/CT and CECT. Malignant liver lesions in the contralat-
eral hepatic lobe were detected in two patients with colorectal
cancer using image sets D – F (Fig. 4). Thus, additional
lesions were identified in a total of five patients.
In the remaining three patients (change in confidence rating
from grade 3 to 4 in all) with additional metastases on PET/
MR imaging, additional lesions were located in segments that
were already rated as positive for malignancy using image set
B. Thus, the rate of detection of malignant liver lesions was
significantly higher with image set F than with either set C
(P< 0.001) or set D (P< 0.05). The detection rate was also
found to be significantly superior with image set E than with
set C (P< 0.01). No significant differences were found when
comparing the evaluations with image sets E and F (P >0.05),
sets C and D or sets D and E (P >0.05). Thus, the addition of
contrast medium improved the diagnostic detection rate sig-
nificantly, while the addition of diffusion weighting did not
improve the detection rate compared to CE PET/MRI
imaging.
In the per-patient analysis, no significant differences were
found among the evaluations with the different image sets
regarding detection of malignant liver lesions (P >0.05
for all); however, a potential impact on patient management
was achieved in 5 of 55 patients (10 %) using image
sets E and F.
Fig. 1 Size distribution in
relation to abnormal FDG uptake.
Malignant lesions with abnormal
FDG uptake were significantly
larger than those without
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Discussion
The decision to surgically resect or locally treat primary or
secondary liver malignancies is based on both technical and
oncological criteria, mainly related to number, size and ana-
tomical location of metastases [1]. Thus, more accurate detec-
tion and localization of liver metastases with one image set as
compared with another may result in a change in therapeutic
management. To the best of our knowledge, our results for the
first time show the potential use of PET/MR imaging for the
detection of liver metastases in oncological patients and dem-
onstrate the necessary MR sequences in the clinical setting
using a trimodality PET/CT/MR setup.
Only a few studies have compared lesion detection and
characterization between PET/CT and retrospectively fused
PETand MR imaging studies (hereon referred to as PET−MR
in contrast to integrated PET/MR) [12, 13]. In line with these
studies, our results similarly indicate that in the characteriza-
tion of liver metastases PET/MR imaging has a better rate of
detection with higher confidence than PET/CECT. PET/MR
with DWI or dynamic CE MR sequences demonstrated a
significantly higher accuracy in the detection of liver metas-
tases than both PET/CECT and PET/MR with T1-W and T2-
W sequences alone. The higher accuracy of DWI and CEMR
imaging as compared with T1-W and T2-W imaging in the
detection of liver lesions can be explained by the higher
lesion-to-liver contrast in the former sequences [20, 21]. Al-
though there is evidence that DWI and PET/CTshow a similar
accuracy in predicting pathological response, the combined
use of DWI and PET may improve the specificity of the
examination, as demonstrated in patients with breast cancer
[22]. However, in our study the rates of detection of liver
metastases with PET/MR with DWI compared to PET/MR
with CE MR images were similar (detection rates with image
sets D and E not significantly different), which is in line with
the findings of previous studies comparing DWI and CE MR
imaging [15]. Notably, no additional benefit was found when
DWI was added to dynamic CE MR images. The addition of
contrast medium had the highest impact on the diagnostic
detection rate, while the addition of DWI appeared inferior
(detection rates with image sets D and C not significantly
different, but the detection rate with set E was superior to that
with set C). Therefore, we recommend dynamic CE MR
sequences be added to provide higher confidence in lesion
characterization (i.e. changes from indeterminate to malignant
grading) rather than lesion detection [23].
The improved detection of liver metastases with PET/MR
imaging was pronounced in those with small malignant liver
lesions, which were regularly not associated with abnormal
FDG uptake. The difficulties in detection of liver lesions
smaller than 10 mm by PET/CT are attributed to the fact that
small liver metastases usually do not show abnormal FDG
uptake, and even on PET/CECT lesion-to-liver contrast can beTa
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too low for adequate lesion detection. These results are in line
with those reported previously demonstrating a significantly
higher diagnostic confidence with retrospectively fused PET–
MR images than with PET/CT in subcentimetre metastases
[12, 13]. In these latter studies, PET–MR data however were
created virtually by retrospective image fusion of PET and
MR scans which were acquired with different scanners and at
different time points with up to 30 days between scans. In our
study, we used a trimodality PET/CT/MR set-up that is of
particularly high interest for comparison and diagnostic
evaluation all three modalities since data are acquired in a
single measurement session without the need for patient repo-
sitioning. Also, in one of the studies mentioned above intra-
venous contrast material was not administered but low-dose
non-enhanced CT only was used [12]; however, CECT is
known to affect liver metastasis detection [24].
With respect to patient selection for potentially curative
surgical resection, even the presence multiple metastases in
both liver lobes is no longer a contraindication [7]. Therefor,
imaging assessment affects patient outcome and is a sine qua
Fig. 2 Receiver operating
characteristic curves for the
different image sets adjusted
for the confidence levels of the
two readers for liver lesion
characterization with image
set B as the standard of reference
including all lesions (a) and
Including only lesions without
abnormal FDG uptake (b). Note
the pronounced differences
between image sets
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non for the use of such treatment regimens [1]. As proven by
imaging follow-up, PET/MR including DWI allowed the de-
tection of liver metastasis in one additional patient, whereas
the addition of dynamic CE MR imaging led to the detection
of additional liver metastases in three patients who were rated
negative on PET/CECT. Moreover, MR imaging with either
DWI or CE MR detected metastases in contralateral hepatic
lobes in two patients with colorectal cancer with crucial
Fig. 3 A 65-year-old patient with multiple liver metastases due to colon
cancer. a , b Contrast-enhanced abdominal CT imaging: the CT image (a)
clearly shows one large confluent lesion (asterisk) and the fused PET/CT
image (b) shows two smaller hypodense lesions (arrows) that demon-
strate abnormal FDG uptake. c–h MR imaging: all lesions are clearly
visible on T2-W (c) and DW MR images (e) as well as on the corre-
sponding fused PET/MR images (d and f , respectively); T1-W images
show rim enhancement after administration of contrast material (g) in
lesions of abnormal FDG uptake (h)
Fig. 4 A 57-year-old patient with liver metastases due to rectal cancer. a ,
b Hepatic metastasis with abnormal FDG uptake is clearly seen in
segment II on both the PET/MR image with T2-weighting (a arrow)
and the PET/CT image after contrast material administration (b arrow).
c , d No lesion or abnormal FDG uptake is apparent in hepatic segment V
on the CECT image (c liver window setting) or the PET/CT image (d). e ,
f The T2-W MR image shows one additional suspicious subcentimetre
lesion (e arrowhead) with metabolic activity comparable to that of
normal liver tissue on fused the PET/MR image (f). g The lesion is
similarly delineated on the DW MR image (arrowhead). Metastasis
was confirmed by growth on follow-up imaging 4 month later as well
as by intraoperative biopsy performed during segment-oriented resection
of segment II. h Percutaneous radiofrequency ablation (arrow) was
subsequently performed but metastasis was not locally controlled with
recurrence anteriorly as shown on the MR image obtained
2 months after treatment
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importance to potentially curative treatment. Thus, PET/MR
imaging led to a potential diagnostic impact in 10 % of the
patients in our cohort irrespective of extrahepatic disease.
Regarding whole-body staging for extrahepatic metastatic
disease, preliminary studies have indicated that PET/MR im-
aging with T1-W and T2-W sequences yields accuracies sim-
ilar to that of PET/CT [25, 26]. For a potential PET/MR
imaging strategy, we therefore suggest that T1-W and T2-W
imaging suffice if extensive extrahepatic disease is detected,
whereas dynamic CEMR – or at least DWI – should be added
for accurate local hepatic assessment in patients with non-
extensive disease. Diagnostic T1-Wand T2-W images may be
acquired during or prior to PET while further MR sequences
of the abdomen could simply be added immediately after
involving less than 10 min additional scan time [27] which
would reduce scanner time and increase patient throughput.
Thus we believe that dedicated PET/MR imaging is an in-
triguing one-stop-shop technique for patients with cancer of
the gastrointestinal tract and potentially metastatic liver
disease.
Last but not least, MR sequences suitable not only for
diagnostic purposes but also for attenuation correction have
to be acquired when imaging with novel hybrid PET/MR
scanners [28]. Our experiments comprised Dixon-based T1-
W imaging that has been shown to enable accurate MR-based
attenuation correction in most soft tissues without affecting
either the quantification of FDG uptake or study interpretation
[29, 30].
Limitations
Our protocol did not include either multiphase CT scanning
(i.e. arterial and portal venous) or dual time point PET [31]. In
addition, we did not administer a hepatocyte-specific contrast
material (e.g. gadolinium-ethoxybenzyl-diethylenetriamine
pentaacetic acid) that is known to improve the sensitivity for
detecting liver metastases [12]. The study was conducted in a
rather heterogeneous and small patient population. However,
all primary tumours originated from the gastrointestinal tract
and primarily metastasized to the liver. We focused on evalu-
ation of the liver, because PET/MR is thought to be especially
beneficial in this organ, and targeted therapies for liver metas-
tases require exact staging of liver disease. Last but not least,
imaging and not histopathology served as the standard of
reference. An independent histopathological gold standard
could not be obtained in all patients for ethical and practical
reasons.
Conclusion
PET/MR imaging with T1-Wand T2-W sequences results in a
diagnostic accuracy for liver metastases similar to that of
PET/CECT imaging. To significantly improve the
characterization of liver lesions, we recommend the use of
dynamic CE imaging sequences.When application of contrast
medium is not possible (e.g. in a patient with renal failure), the
addition of DWI might be considered as an alternative. As-
sessment by PET/MR imaging has a diagnostic impact on
clinical decision making.
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